No alternative for Phosphagenics
Wednesday, 24 September, 2008
Phosphagenics (ASX: POH) will cease trading on the Alternative Investment Market (AIM) of the British stock exchange.
According to Phosphagenics, monthly turnover of the company's AIM shares has decreased since listing four years ago, whereas turnover on the company's ASX shares have increased.
The Melbourne company has begun a Phase I clinical trial of its patented delivery system, TPM, for the topical delivery of the pain relief drug lidocaine.
The trial is being conducted at the Centre for Pharmaceutical Research at the University of South Australia.
The company expects early results in the first quarter of 2009.
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
